Tango Therapeutics (TNGX) Net Equity Issued and Repurchased (2020 - 2024)

Tango Therapeutics' (TNGX) quarterly Net Equity Issued and Repurchased came in at $41.7 million in Q1 2024, up 166792.0% quarter-over-quarter from $25000.0 in Q4 2020.

Tango Therapeutics (TNGX) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends

Tango Therapeutics' Net Equity Issued and Repurchased history runs 2 years deep, the most recent figure standing at $41.7 million for Q1 2024.

  • On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $41.7 million in Q1 2024; TTM through Sep 2024 was $41.7 million, a N/A change from a year earlier, with the FY2020 full-year figure at $25000.0, changed N/A from the prior year.
  • Net Equity Issued and Repurchased rose to $41.7 million in Q1 2024 per TNGX's latest filing, from $25000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $41.7 million in Q1 2024 and bottomed at $25000.0 in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Tango Therapeutics 3.94 Bn 3.78 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2024 41.72 Mn
Mar 31, 2024 41.72 Mn
Dec 31, 2020 25,000.00
Dec 31, 2020 25,000.00
Sep 30, 2020 25,000.00
Sep 30, 2020 25,000.00
Jun 30, 2020 25,000.00
Jun 30, 2020 25,000.00